Jonas Leonhardt, Johann Pratschke, Jürgen Behr, Jeremias Götschke, Philipp Jurmeister, Diego Kauffmann-Guerrero, Frederick Klauschen, Laura Lambrecht, Paula Mras, Christian Schneider, Blerina Resuli, Amanda Tufman
Tarlatamab is a bispecific T-cell engager used for the treatment of small cell lung cancer (SCLC). Patients with a history of solid organ transplantation carry an elevated risk of malignancy yet are excluded from most clinical trials. We report the first case of Tarlatamab use in a liver transplant recipient with SCLC, resulting in marked tumor response and a favorable safety profile without evidence of graft rejection.